Antagonism at 5-HT2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats

Pharmacology Biochemistry and Behavior

Volumn 68, Issue 3, 2001, Pages 363-370

  Wadenberg, Marie Louise G ^a,b,d   Browning, Jeff L ^a   Young, Keith A ^b,c   Hicks, Paul B ^a,b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atypical antipsychotic drugs; Catalepsy; Conditioned avoidance response behavior; Dopamine D2 receptor; Rat; Serotonin 2A receptor

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; RACLOPRIDE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BIOCHEMISTRY; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ELECTROPHYSIOLOGY; EXTRAPYRAMIDAL SYMPTOM; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SYMPTOM;

ANIMALS; AVOIDANCE LEARNING; CATALEPSY; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXTRAPYRAMIDAL TRACTS; FLUOROBENZENES; HALOPERIDOL; MALE; PIPERIDINES; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0035022182     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(00)00483-4     Document Type: Article

References (62)

1. Ahlenius S, Hillegaart V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and postsynaptic inhibition of dopaminergic neurotransmission. Pharmacol, Biochem Behav 1986;24:1409-15.
2. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopamine system. Naunyn-Schmiedeberg's Arch Pharmacol 1995;352:374-85.
3. Andrée B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin Ch, Farde L. Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. J Clin Psychopharmacol 1998;18:317-23.
4. Angrist GM, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms of schizophrenia. Psychopharmacology 1980;72:17-9.
5. Amt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982;51:321-9.
6. Arnt J, Hyttel J, Back-Lauritsen T. Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol 1986;69:319-24.
7. 2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr Res 1995; 15:153-4.
8. 2A/C antagonist, reverse haloperidol induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 1997;131:57-63.
9. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-203.
10. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995;10:207-13.
11. 2 receptor antagonist. Soc Neurosci Abstr 1990;16:1037.
12. 2/1C antagonist, and negative symptoms in schizophrenia: a place-bo-controlled double-blind trial. Br J Psychiatry 1993;163:451-5.
13. Egbe P, Engel J, Gustafsson B, Christensson E. Amperozide and conditioned behaviour in rats: potentiation by classic neuroleptics and α-methylparatyrosine. Pharmacol Toxicol Suppl 1990;1:18-21.
14. Ellenbroek BA, Cools AR. The paw test: an animal model for neuroleptic drugs which fulfills the criteria for pharmacological isomorphism. Life Sci 1988;42:1205-13.
15. Ellenbroek BA, Prinssen EP, Cools AR. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs: a paw test study in rats. Eur J Neurosci 1994;6:1-8.
16. Elliott PJ, Walsh DM, Close SP, Higgins GA, Hayes AG. Behavioural effects of serotonin agonists and antagonists in the rat and marmoset. Neuropharmacology 1990;29:949-56.
17. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central Dl and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
18. Fink JS, Smith GP. Mesolimbic and mesocortical dopaminergic neurons are necessary for normal exploratory behavior in rats. Neurosci Lett 1980;17:61-5.
19. Geyer MA, Krebs-Thomson K, Varty GB. The effects of M100907 in pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia. Neuropsychopharmacology 1999;21: S134-42.
20. Heimer L, Alheid GF, Zahm DS. Basal forebrain organization: an anatomical framework for motor aspects of drive and motivation. In: Kalivas PW, Barnes CD, editors. Limbic motor circuits and neuropsychiatry. Boca Raton, FL: CRC Press, 1993. pp. 1-43.
21. Hicks PB, Browning J, Barwick S, Jones D, Wadenberg M-L, Richter JT, Young KA. M 100,907 acts at both the nucleus accumbens and the prefrontal cortex to mediate the enhancement of the suppression of conditioned avoidance response by haloperidol. Schizophr Res 1999; 36:115.
22. 2A receptors with Carbon-11-MDL 100,907. J Nucl Med 1998;39:208-14.
23. Janssen PA. The pharmacology of haloperidol. Int J Neuropsychiatry 1967;3(Suppl l):10-8.
24. 2A receptor ligand. Naunyn-Schmiedeberg's Arch Pharmacol 1996;354:205-9.
25. Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996;124:35-9.
26. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996;277:968-81.
27. 2 receptors in the rat brain. Biochem Pharmacol 1985;34:2251-9.
28. Korsgaard S, Friis T. Effects of mianserin in neuroleptic-induced parkinsonism. Psychopharmacology 1986;88:109-11.
29. Li CC. Introduction to experimental statistics. New York: McGraw-Hill, 1964. pp. 207-26.
30. 3H]MDL 100,907. Naunyn-Schmiedeberg's Arch Pharmacol 1997;356:446-54.
31. 2A serotonin receptors selectively in primate brain. Neuropharmacology 1998;37:1147-58.
32. Meco G, Bedini L, Bonifati V, Sonsini U. Ritanserin in tardive dyskinesia: a double-blind crossover study versus placebo. Curr Ther Res 1989;46:884-94.
33. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:S18-27.
34. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995a;3:64-75.
35. Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995b. pp. 1277-86.
36. Mogenson GJ, Jones DL, Yim CY From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 1980;14:69-97.
37. Moghaddam B, Bunney BB. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990;54:1755-60.
38. Neal-Beliveau BS, Joyce JN, Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993;265:207-17.
39. Owens MJ, Risch SC. Atypical antipsychotics. In: Schatzberg AF, Nemeroff CB, editors. Psychopharmacology. Washington, DC: American Psychiatric Press, 1995. pp. 263-80.
40. Prinssen PM, Kleven MS, Koek W. Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 1996;128:191-7.
41. 2C receptor antagonist. Br J Pharmacol 1999;126:572-4.
42. 2 receptor blocker. Drug Dev Res 1986;8:205-11.
43. 2A receptor antagoist MDL 100,907 increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995;273:273-9.
44. 2A receptors in antipsychotic activity. Life Sci 1995;56:2209-22.
45. Seeman P. Receptor selectivities of atypical neuroleptics. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1992. pp. 145-54.
46. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123-34.
47. Seeman P, Corbett R, Van Toi HHM. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997;16:93-122.
48. Siegel S, Castellan NJ. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1988.
49. 2C receptors. Behav Pharmacol 1995;6:839-42.
50. 2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 1993;266:684-91.
51. 2 antagonism. In: Vanhoutte PM, Saxena PR, Paoletti R, Brunello N, Jackson AS, editors. Serotonin: from cell biology to pharmacology and therapeutics. Dordrecht, Netherlands: Kluwer Academic Publishing, 1993. pp. 263-76.
52. 2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 1999;20:311-21.
53. Wadenberg M-L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm 1992;89:49-59.
54. Wadenberg M-L. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 1996;20:325-39.
55. 2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat. Eur J Pharmacol 1995;294:247-51.
56. Wadenberg M-L, Hicks PB. The conditioned avoidance response test reevaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999;23:851-62.
57. Wadenberg M-L, Ericson E, Magnusson O, Ahlenius S. Suppression of conditioned avoidance behavior by the local application of (-) sulpiride into the ventral, but not the dorsal, striatum of the rat. Biol Psychiatry 1990;28:297-307.
58. 2 receptor blocking agent ritanserin in the rat. Eur Neuropsychopharmacol 1996;6:305-10.
59. 2A receptor antagonist MDL 100,907. Biol Psychiatry 1998a;44:508-15.
60. Wadenberg M-L, Young KA, Trompler RA, Zavodny RA, Richter TJ, Hicks PB. A novel computer controlled conditioned avoidance apparatus for rats. J Pharmacol Toxicol Methods 1998b;38:211-5.
61. 2 receptor occupancy and catalepsy in rats. Psychopharmacology 2000;150:422-9.
62. 2A and muscarinic receptors. Psychopharmacology 1999;141:267-78.